BSX Share Price | Boston Scientific Corp. Stock Analysis & Recommendation

Q: How big is Boston Scientific Corp.?

Market Cap: As of Jun 18, Boston Scientific Corp. has a market capitalization of 177,288.56 million, categorizing it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Boston Scientific Corp. reported net sales of 17,553.00 million and a net profit of 2,024.00 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 21,770.00 million and total assets of 39,395.00 million.

Q: What does Boston Scientific Corp. do?

Overview:Boston Scientific Corporation is a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties, operating within the retailing industry and classified as a large-cap company.Financial Snapshot:Most recent Net Sales: 4,663 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 672 Million (Quarterly Results - Mar 2025) Market-cap: USD 177,288.56 Million (Large Cap)Key Metrics:P/E: 86.00 Dividend Yield: 5,863.88% Debt Equity: 0.47 Return on Equity: 9.28% Price to Book: 7.98Contact Details:Address: 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA: 01752-1234 Tel: 1 508 6834000 Website: https://www.bostonscientific.com/

Q: Is Boston Scientific Corp. overvalued or undervalued?

As of 23 July 2025, Boston Scientific Corp. has moved from very expensive to attractive, indicating a significant shift in its valuation perspective. The company appears to be undervalued, especially when considering its P/E ratio of 86, which is notably higher than the peer average P/E of 73.71, and an EV to EBITDA ratio of 44.86 compared to the peer average of 45.38. Additionally, the PEG ratio stands at 6.37, suggesting that the stock may not be priced favorably relative to its earnings growth potential.In terms of peer comparison, McKesson Corp. has a P/E of 57.25 and Cencora, Inc. has a P/E of 40.09, both of which indicate that Boston Scientific's valuation is higher, yet it is classified as attractive due to its growth prospects. Despite recent underperformance with a 1-week return of -5.86% compared to the S&P 500's 1.05%, the company has shown resilience with a 3-year return of 135.56%, significantly outperforming the S&P 500's 70.41% in the same period, reinforcing its potential for future growth.

Q: Is Boston Scientific Corp. technically bullish or bearish?

As of 3 October 2025, the technical trend for Boston Scientific Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings, which are both mildly bearish, and a bearish signal from the weekly Bollinger Bands. The daily moving averages indicate a mildly bullish trend, but this is overshadowed by the overall bearish indicators from the KST and Dow Theory on both weekly and monthly time frames. In terms of performance, Boston Scientific has underperformed the S&P 500 over the past week and month, with returns of -0.35% and -9.81% compared to the S&P 500's 1.09% and 4.15%, respectively. However, it has outperformed the benchmark over longer periods, such as the 3-year and 5-year returns.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.36 M

Shareholding (Mar 2026)

FII

23.86%

Held by 649 FIIs

DII

42.38%

Held by 177 DIIs

Promoter

0.37%

How big is Boston Scientific Corp.?

22-Jun-2025

As of Jun 18, Boston Scientific Corp. has a market capitalization of $177.29 billion, with recent net sales of $17.55 billion and a net profit of $2.02 billion over the last four quarters.

View full answer

What does Boston Scientific Corp. do?

22-Jun-2025

Boston Scientific Corporation develops and markets medical devices for various interventional specialties, with recent net sales of $4.66 billion and a net profit of $672 million. The company has a market cap of approximately $177.29 billion and key metrics include a P/E ratio of 86.00 and a dividend yield of 5,863.88%.

View full answer

Who are in the management team of Boston Scientific Corp.?

22-Jun-2025

As of March 2022, the management team of Boston Scientific Corp. includes Michael Mahoney (Chairman, President, CEO), Edward Ludwig (Lead Independent Director), and independent directors Nelda Connors, Charles Dockendorff, Yoshiaki Fujimori, and Donna James. They oversee the company's strategic direction and operations.

View full answer

Is Boston Scientific Corp. overvalued or undervalued?

20-Sep-2025

As of July 23, 2025, Boston Scientific Corp. is considered attractive despite a high P/E ratio of 86 compared to peers, due to its strong growth potential and impressive long-term performance, having returned 135.56% over three years, significantly outpacing the S&P 500.

View full answer

Is Boston Scientific Corp. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Boston Scientific Corp. shows a mildly bearish trend influenced by bearish MACD readings and Bollinger Bands, despite recent underperformance against the S&P 500, although it has outperformed over the longer 3- and 5-year periods.

View full answer

Compare Boston Scientific Corp. with Similar Stocks

McKesson Corp.Cencora, Inc.Cardinal Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Healthy long term growth as Net Sales has grown by an annual rate of 12.73%

OPERATING CASH FLOW(Y) Highest at USD 4,285 MM
ROCE(HY) Highest at 11.71%
NET SALES(Q) Highest at USD 5,061 MM

Mojo Parameters

Stock DNA

Industry

Retailing

Market cap

USD 121,935 Million (Large Cap)

P/E

36.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.39

Return on Equity

13.88%

Price to Book

5.03

Revenue and Profits:

Net Sales:

5,203 Million

(Quarterly Results - Mar 2026)

Net Profit:

1,339 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.83%

6 Months

-43.44%

1 Year

-46.02%

2 Years

-22.96%

3 Years

9.76%

4 Years

38.48%

5 Years

31.16%

Boston Scientific Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

15.16%

EBIT Growth (5y)

46.76%

EBIT to Interest (avg)

5.69

Debt to EBITDA (avg)

2.84

Net Debt to Equity (avg)

0.47

Sales to Capital Employed (avg)

0.52

Tax Ratio

18.32%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

94.32%

ROCE (avg)

6.99%

ROE (avg)

7.79%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.03

EV to EBIT

32.25

EV to EBITDA

24.14

EV to Capital Employed

3.91

EV to Sales

6.54

PEG Ratio

0.44

Dividend Yield

ROCE (Latest)

12.12%

ROE (Latest)

13.88%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 205 Schemes (33.36%)

Foreign Institutions

Held by 649 Foreign Institutions (23.86%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -1.57% vs 4.36% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 99.85% vs -11.26% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,203.00",
          "val2": "5,286.00",
          "chgp": "-1.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,426.00",
          "val2": "1,577.00",
          "chgp": "-9.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "93.00",
          "val2": "34.00",
          "chgp": "173.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "37.00",
          "val2": "-206.00",
          "chgp": "117.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,339.00",
          "val2": "670.00",
          "chgp": "99.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "206.60%",
          "val2": "229.30%",
          "chgp": "-2.27%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 19.87% vs 17.61% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 56.66% vs 15.95% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "20,074.00",
          "val2": "16,747.00",
          "chgp": "19.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,439.00",
          "val2": "3,904.00",
          "chgp": "39.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "325.00",
          "val2": "387.00",
          "chgp": "-16.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-533.00",
          "val2": "-32.00",
          "chgp": "-1,565.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,892.00",
          "val2": "1,846.00",
          "chgp": "56.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "202.80%",
          "val2": "157.30%",
          "chgp": "4.55%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

5,203.00

5,286.00

-1.57%

Operating Profit (PBDIT) excl Other Income

1,426.00

1,577.00

-9.58%

Interest

93.00

34.00

173.53%

Exceptional Items

37.00

-206.00

117.96%

Consolidate Net Profit

1,339.00

670.00

99.85%

Operating Profit Margin (Excl OI)

206.60%

229.30%

-2.27%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -1.57% vs 4.36% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 99.85% vs -11.26% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

20,074.00

16,747.00

19.87%

Operating Profit (PBDIT) excl Other Income

5,439.00

3,904.00

39.32%

Interest

325.00

387.00

-16.02%

Exceptional Items

-533.00

-32.00

-1,565.62%

Consolidate Net Profit

2,892.00

1,846.00

56.66%

Operating Profit Margin (Excl OI)

202.80%

157.30%

4.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 19.87% vs 17.61% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 56.66% vs 15.95% in Dec 2024

All Annual Results

Company CV

About Boston Scientific Corp.

Boston Scientific Corp.

Retailing

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Company Coordinates

Company Details

300 BOSTON SCIENTIFIC WAY , MARLBOROUGH MA : 01752-1234

Tel: 1 508 6834000

https://www.bostonscientific.com/

Registrar Details